The Federal Register published notice E6-17284, attributed to FDA and its parent HHS department, on 2006-10-18. Its official title is “Summaries of Medical and Clinical Pharmacology Reviews of Pediatric Studies; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide.
The Federal Register published notice E6-16091, attributed to FDA and its parent HHS department, on 2006-10-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; NATRECOR,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide.
The Federal Register published notice E6-16086, attributed to FDA and its parent HHS department, on 2006-10-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; BYETTA,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.
The Federal Register published notice E6-15554, attributed to FDA and its parent HHS department, on 2006-09-20. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; FUZEON,” and PeptideScanner's exact reviewed identity mapping connects the document to Enfuvirtide.
The Federal Register published notice E6-12571, attributed to FDA and its parent HHS department, on 2006-08-03. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; IPLEX,” and PeptideScanner's exact reviewed identity mapping connects the document to Mecasermin.
The Federal Register published notice E6-9414, attributed to FDA and its parent HHS department, on 2006-06-16. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; SYMLIN,” and PeptideScanner's exact reviewed identity mapping connects the document to Pramlintide.
The Federal Register published notice E6-9440, attributed to FDA and its parent HHS department, on 2006-06-16. Its official title is “Merck & Co., Inc., et al.; Withdrawal of Approval of 65 New Drug Applications and 52 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon.
The Federal Register published notice E6-9225, attributed to FDA and its parent HHS department, on 2006-06-14. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; CUBICIN,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.
The Federal Register published notice E6-9138, attributed to FDA and its parent HHS department, on 2006-06-13. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; INCRELEX,” and PeptideScanner's exact reviewed identity mapping connects the document to Mecasermin.
The Federal Register published notice E6-9031, attributed to FDA and its parent HHS department, on 2006-06-09. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; CETROTIDE,” and PeptideScanner's exact reviewed identity mapping connects the document to Cetrorelix.
The Federal Register published notice E6-3712, attributed to FDA and its parent HHS department, on 2006-03-15. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; PRIALT,” and PeptideScanner's exact reviewed identity mapping connects the document to Ziconotide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 077414 with status AP dated 2006-03-07, and names desmopressin acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 077450 with status AP dated 2006-02-10, and names octreotide acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 077457 with status AP dated 2006-02-10, and names octreotide acetate among the application record's active ingredients.
The Federal Register published notice E6-1069, attributed to FDA and its parent HHS department, on 2006-01-30. Its official title is “Anti-Infective Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.
The official Drugs@FDA dataset lists original submission 1 for ANDA 077122 with status AP dated 2006-01-25, and names desmopressin acetate among the application record's active ingredients.